Marta Lustig

Marta Lustig

Auto-generated profile, based on publicly available information

Marta Lustig

Division of Stem Cell Transplantation and Cellular Immunotherapies, Department of Medicine II, University Medical Center Schleswig-Holstein and Christian-Albrechts-University, Kiel, Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
SFStian Foss
Stian Foss
SSSiri Aastedatter Sakya
Siri Aastedatter Sakya
LALeire Aguinagalde
Leire Aguinagalde
MLMarta Lustig
Marta Lustig
JSJutamas Shaughnessy
Jutamas Shaughnessy
JAJan Terje Andersen
Jan Terje Andersen
Monoclonal IgG antibodies constitute the fastest growing class of therapeutics. Thus, there is an intense interest to design more potent antibody formats, where long plasma half-life is a commercially competitive differentiator affecting dosing, frequency of administration and thereby potentially patient compliance. Here, we report on an Fc-engineered variant with three amino acid substitutions Q311R/M428E/N434W (REW), that enhances plasma half-life and mucosal distribution, as well as allows for needle-free delivery across respiratory epithelial barriers in human FcRn transgenic mice. In addition, the Fc-engineered variant improves on-target complement-mediated killing of cancer cells as well as both gram-positive and gram-negative bacteria. Hence, this versatile Fc technology should be broadly applicable in antibody design aiming for long-acting prophylactic or therapeutic interventions.

1 February 2025 in PNAS Nexus
Verified
Journal Article
Open access
SMSimone Mester
Simone Mester
CCChilam Chan
Chilam Chan
MLMarta Lustig
Marta Lustig
SFStian Foss
Stian Foss
JJJ H Marco Jansen
J H Marco Jansen
JAJan Terje Andersen
Jan Terje Andersen
Most therapeutic antibodies are based on immunoglobulin G (IgG) due to their potent effector functions and long plasma half-life. However, also monomeric IgA has emerged as an attractive candidate for cancer treatment as, upon specific binding to tumor cells, it can activate myeloid cells, like polymorphonuclear leukocytes and macrophages, to kill the tumor cells by engaging the Fc α receptor I (FcαRI). Despite this favorable property, human IgA has a short plasma half-life in both mice and humans, which is clearly limiting preclinical studies in a translational perspective. Here, we report on albumin-equipped designs of human IgA antibodies that are long acting due to tailored binding to the human form of neonatal Fc receptor (FcRn), which is a natural plasma half-life regulator of albumin. Importantly, this was achieved without compromising the ability of IgA to engage and activate FcαRI-expressing effector cells for tumor cell killing in vitro and in vivo in a new mouse model transgenic for the human forms of FcRn and FcαRI. We further show that the potency of the engineered long-acting human IgA against tumor cells with intermediate target antigen expression levels could be enhanced by myeloid checkpoint inhibitors targeting the signal regulatory protein α-CD47 axis.

13 August 2025 in bioRxiv
Verified
Preprint
Open access
MKM. Kowol
M. Kowol
MLM. Lustig
M. Lustig
AHA.M. Hartmann
A.M. Hartmann
IPI.C. van der Peet
I.C. van der Peet
MJM. Jansen
M. Jansen
TVT. Valerius
T. Valerius
Enhancing myeloid effector cell recruitment may improve immunotherapy by monoclonal antibodies – including that against acute lymphoblastic leukemia (ALL). To assess expression of target antigens in B-ALL, we compared mRNA profiling of 559 patient leukemia samples across 18 molecular subtypes with that of representative cell lines. The latter served as target cells to compare human IgG1 or IgA2 variants against CD19, CD20 or CD38 in antibody-dependent cellular phagocytosis (ADCP) by macrophages and antibody-dependent cell-mediated cytotoxicity (ADCC) by polymorphonuclear leukocytes (PMN). Interestingly, antibodies against broadly expressed CD19 were negligibly effective in mediating ADCP or ADCC. Antibodies against CD20 or CD38, the former variably expressed across subtypes, triggered ADCP by macrophages both as IgG1 and IgA2. However, PMN mediated ADCC against CD20 or CD38 was only observed with IgA2 variants, but not with respective IgG1 antibodies. Blocking the myeloid checkpoint molecule CD47 with a CD47 antibody or a soluble SIRPα-Fc fusion protein enhanced ADCP and ADCC by IgA2 antibodies. The binding site for SIRPα on CD47 contains an N-terminal pyroglutamate (pGlu), whose formation is catalyzed by glutaminyl-peptide cyclotransferase like (QPCTL). The direct involvement of pGlu in CD47/SIRPα interactions was shown by using engineered CD47 variants. Both CD47 and QPCTL were broadly expressed across BCP-ALL subtypes, indicating QPCTL inhibitors as additional therapeutic option. Importantly, the combination of anti-CD38 IgA2 and CD47 blockade was effective against xenografted B-ALL cells in human FcαRI (CD89) transgenic (tg) NXG mice. Together, these studies support the combination of anti-CD38 IgA2 with CD47 interference to improve myeloid effector cell recruitment for immunotherapy of B-ALL. Data sharing statement: RNA-Seq data from BCP-ALL patients and B cells from healthy donors are available in the European Genome-Phenome Archive (EGA) accession numbers EGAS00001006107 and EGAS00001007305, respectively. Mass spectrometry data of analyzed proteins will be made available after manuscript acceptance on PRIDE - PRoteomics IDEntifications Database. Graphical Key points: IgG1 and IgA2 antibodies against CD38 or CD20 were effective in recruiting macrophages for ADCP, but only IgA2 triggered ADCC by PMN Myeloid effector cell activation was enhanced by interfering with the CD47/SIRPα axis, especially when IgA2 antibodies were applied

17 November 2025 in bioRxiv
Verified
Preprint
Open access
MKMiriam Kelm
Miriam Kelm
NNNourhan Nasr
Nourhan Nasr
SBSonja Bendig
Sonja Bendig
DKDieter Kabelitz
Dieter Kabelitz
MLMarta Lustig
Marta Lustig
GCGuranda Chitadze
Guranda Chitadze
Blinatumomab (BLN) is a bispecific T-cell engager that has revolutionized the treatment of B-cell precursor acute lymphoblastic leukemia (BCP-ALL), significantly improving outcomes in both adults and children. By simultaneously binding to CD19 on B cells and CD3 on T cells, BLN triggers target cell-dependent T-cell activation, resulting in the cytolysis of CD19 + BCP-ALL cells. Despite the remarkable clinical advancements achieved with BLN, the immunological mechanisms underlying treatment response or failure remain poorly characterized. γδ T cells are attractive candidates for adoptive T–cell therapy due to potent cytotoxicity, capacity to present antigens, broad lysis of different tumor entities, and low alloreactivity. Because γδ T cells can also be redirected by BLN, we systematically studied BLN–driven effector functions of conventional αβ and unconventional γδ T cells. We evaluated cytotoxicity and cytokine/effector release in freshly isolated and in vitro-expanded αβ and γδ T cells from healthy adults against CD19⁺ BCP-ALL lines (NALM-6, HAL-01), and profiled dynamic phenotypic alterations by multiparametric flow cytometry. CD19⁺ targets were consistently reduced in the presence of BLN. Freshly isolated αβ, especially CD8⁺, displayed superior BLN-mediated cytotoxicity as compared to γδ T cells, with donor-dependent variability in γδ killing. Notably, zoledronate-expanded Vγ9Vδ2 γδ T-cell lines achieved cytotoxicity comparable to PHA-expanded αβ cells. However, γδ T-cell-killing benefited from higher BLN concentration when challenged with high tumor load. BLN induced CD3 down-modulation in αβ T cells but not in γδ T cells, alongside higher soluble Fas ligand in αβ cultures, consistent with stronger early activation, preceding activation-induced cell death. γδ T cells showed no such changes, suggesting reduced susceptibility to activation-induced cell death. Single-cell RNA and flow analyses corroborated these findings, showing robust activation/exhaustion programs in αβ T cells and a stable effector-memory state with low checkpoint expression in γδ T cells. Together, these data reveal subset–specific BLN responses and support expanded Vγ9Vδ2 γδ T cells as a rational adoptive partner to BLN — particularly in settings of favorable antigen density/low tumor burden — providing complementary cytotoxicity with potentially reduced inflammatory liability. These findings provide a framework for combining γδ T-cell-based therapies in BLN-treated patients for improving BLN efficacy in BCP-ALL patients.

5 May 2026 in Blood Neoplasia
Verified
Journal Article
Open access
MLMarta Lustig
Marta Lustig
MKMaja Kowol
Maja Kowol
AHAlina M. Hartmann
Alina M. Hartmann
IPIda van der Peet
Ida van der Peet
MJMarco J.H. Jansen
Marco J.H. Jansen
TVThomas Valerius
Thomas Valerius
• IgG1 and IgA2 antibodies against CD38 or CD20 were effective in recruiting macrophages for ADCP, but only IgA2 triggered ADCC by PMN. • Myeloid effector cell activation was enhanced by interfering with the CD47/SIRPα axis, especially when IgA2 antibodies were applied.

7 July 2026 in EMBO Molecular Medicine
Verified
Journal Article
Open access
MCMariya Chernyavska
Mariya Chernyavska
KHK Patricia Hartmann
K Patricia Hartmann
JJJ H Marco Jansen
J H Marco Jansen
NBNiklas Baumann
Niklas Baumann
JKJonas Kolibius
Jonas Kolibius
Wouter VerdurmenWouter Verdurmen
Wouter Verdurmen
Despite advances in IgG-based cancer immunotherapy, challenges remain in effectively engaging innate immune responses against solid tumors. Here, IgA antibodies hold promise due to their ability to activate neutrophils and macrophages. We present a novel retargeted adenovirus-mediated approach that transforms cancer cells into “biofactories” for localized production of monomeric or dimeric IgA antibodies and a CD47 blocker to potentiate the effect of IgA antibodies. With our approach, tumor cells effectively produced IgA antibodies against tumor antigens such as EGFR or EpCAM and a soluble SIRPα-Fc fusion protein, which blocks the CD47-SIRPα axis. In a perfused tumor-on-a-chip model, locally produced IgA triggered neutrophil- and macrophage-mediated tumor cell killing, further potentiated by SIRPα-Fc co-production. In FcαRI-transgenic, tumor-bearing mice, intratumoral adenoviral injection induced strong local IgA and SIRPα-Fc expression, immune cell infiltration, and more than 50% tumor volume reduction after a single treatment. We found that dimeric IgA exerts stronger effects than monomeric IgA. Together, these results demonstrate that adenovirus-mediated, tumor-restricted delivery of IgA antibodies and CD47 blockade effectively engages innate immune mechanisms and has therapeutic promise.